In HL, we demonstrated that HL MVs are positive for CD30, the phenotypic marker of HRS cells, and that patients with higher HL stage showed fewer CD30+ MV than low stage HL subjects [36]. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.